Clinical Trial Update: Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial [Phase 2]

View source ↗

Summary

The HOPES trial assessed VM202 for painful diabetic neuropathy in Phase 2 and has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Painful Diabetic Neuropathy

Drugs mentioned

• VM202 (hepatocyte growth factor gene therapy)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Painful Diabetic Neuropathy | Phase 2 | Status: WITHDRAWN